UBS Group’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,228,726
| Closed | -$64.8M | – | 11025 |
|
|
2026
Q1 | $64.8M | Buy |
1,228,726
+902,758
| +277% | +$37.1M | 0.01% | 1384 |
|
|
2025
Q4 | $13.2M | Sell |
325,968
-646,804
| -66% | -$14.9M | ﹤0.01% | 3009 |
|
|
2025
Q3 | $7.31M | Sell |
972,772
-198,847
| -17% | -$1.27M | ﹤0.01% | 3633 |
|
|
2025
Q2 | $4.37M | Buy |
1,171,619
+238,513
| +26% | +$745K | ﹤0.01% | 4023 |
|
|
2025
Q1 | $2.58M | Buy |
933,106
+531,448
| +132% | +$2.17M | ﹤0.01% | 4478 |
|
|
2024
Q4 | $2.23M | Buy |
401,658
+332,260
| +479% | +$2.25M | ﹤0.01% | 4626 |
|
|
2024
Q3 | $579K | Sell |
69,398
-17,934
| -21% | -$148K | ﹤0.01% | 5113 |
|
|
2024
Q2 | $595K | Buy |
87,332
+24,563
| +39% | +$149K | ﹤0.01% | 4872 |
|
|
2024
Q1 | $412K | Sell |
62,769
-45,706
| -42% | -$298K | ﹤0.01% | 5351 |
|
|
2023
Q4 | $704K | Buy |
108,475
+86,931
| +404% | +$460K | ﹤0.01% | 4801 |
|
|
2023
Q3 | $108K | Sell |
21,544
-31,531
| -59% | -$200K | ﹤0.01% | 5779 |
|
|
2023
Q2 | $464K | Buy |
53,075
+47,403
| +836% | +$552K | ﹤0.01% | 4884 |
|
|
2023
Q1 | $67.2K | Buy |
+5,672
| New | +$54.2K | ﹤0.01% | 6218 |
|
|
2022
Q4 | – | Sell |
-3,667
| Closed | -$22K | – | 11144 |
|
|
2022
Q3 | $22K | Buy |
+3,667
| New | +$13.6K | ﹤0.01% | 7270 |
|
|
2022
Q1 | – | Sell |
-3,775
| Closed | -$27K | – | 10890 |
|
|
2021
Q4 | $27K | Buy |
+3,775
| New | +$31.4K | ﹤0.01% | 7506 |
|
|
2021
Q2 | – | Sell |
-2,546
| Closed | -$56K | – | 9819 |
|
|
2021
Q1 | $56K | Buy |
+2,546
| New | +$55.8K | ﹤0.01% | 6433 |
|
Other funds holding TERN
UBS Group's TERN Position: Q2 2026 in Review
UBS Group sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 1,228,726 shares — an estimated $64.8M sold.
UBS Group first reported a position in TERN in Q1 2021 and held it in 16 quarters. The position peaked at $64.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- UBS Group reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 1,228,726 Terns Pharmaceuticals shares in Q2 2026, an estimated $64.8M.
- UBS Group first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 16 quarters.
- UBS Group's Terns Pharmaceuticals position peaked at $64.8M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.